APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Drugs

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

Selected research

Market Structure

Global Oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchOncology Drugs Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Read the full market overview

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

Report Includes

This report provides an overview of the global Oncology Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Oncology Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Oncology Drugs Segment by Company

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen

Sanofi

Bayer

Biogen Idec

Teva

Otsuka

Eisai

Merck KGaA

Gilead Sciences

Oncology Drugs Segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Oncology Drugs Segment by Application

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory or Lung Cancer

Others

Oncology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Oncology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Drugs industry.

Chapter 3: Detailed analysis of Oncology Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncology Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Chemotherapy Table 3. Key Players of Targeted Therapy Table 4. Key Players of Immunotherapy (Biologic Therapy) Table 3. Key Players of Hormonal Therapy Table 4. Key Players of Others Table 5. Global Oncology Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Blood Cancer Table 7. Key Players of Breast Cancer Table 8. Key Players of Gastrointestinal Cancer Table 9. Key Players of Prostate Cancer Table 10. Key Players of Respiratory or Lung Cancer Table 11. Key Players of Others Table 12. Global Oncology Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Oncology Drugs Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Oncology Drugs Market Share by Region (2021-2026) Table 15. Global Oncology Drugs Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Oncology Drugs Market Share by Region (2027-2032) Table 17. Oncology Drugs Industry Trends Table 18. Oncology Drugs Industry Drivers Table 19. Oncology Drugs Industry Opportunities and Challenges Table 20. Oncology Drugs Industry Restraints Table 21. Global Oncology Drugs Revenue by Company (US$ Million) & (2021-2026) Table 22. Global Oncology Drugs Revenue Market Share by Company (2021-2026) Table 23. Global Oncology Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 24. Global Oncology Drugs Key Company Head Office and Area Served Table 25. Global Oncology Drugs Company, Product Type & Application Table 26. Global Oncology Drugs Company Establishment Date Table 27. Global Company Market Concentration Ratio (CR5 and HHI) Table 28. Global Oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 29. Global Oncology Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 31. Global Oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 32. Global Oncology Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Oncology Drugs Revenue Market Share by Type (2027-2032) Table 34. Global Oncology Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 36. Global Oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 37. Global Oncology Drugs Revenue Market Share by Application (2021-2026) Table 38. Global Oncology Drugs Revenue Market Share by Application (2027-2032) Table 39. Roche Company Information Table 40. Roche Business Overview Table 41. Roche Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Roche Oncology Drugs Product Portfolio Table 43. Roche Recent Development Table 44. Celgene Company Information Table 45. Celgene Business Overview Table 46. Celgene Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Celgene Oncology Drugs Product Portfolio Table 48. Celgene Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Novartis Oncology Drugs Product Portfolio Table 53. Novartis Recent Development Table 54. Bristol-Myers Squibb Company Information Table 55. Bristol-Myers Squibb Business Overview Table 56. Bristol-Myers Squibb Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Bristol-Myers Squibb Oncology Drugs Product Portfolio Table 58. Bristol-Myers Squibb Recent Development Table 59. Johnson & Johnson Company Information Table 60. Johnson & Johnson Business Overview Table 61. Johnson & Johnson Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Johnson & Johnson Oncology Drugs Product Portfolio Table 63. Johnson & Johnson Recent Development Table 64. Merck & Co. Company Information Table 65. Merck & Co. Business Overview Table 66. Merck & Co. Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Merck & Co. Oncology Drugs Product Portfolio Table 68. Merck & Co. Recent Development Table 69. AstraZeneca Company Information Table 70. AstraZeneca Business Overview Table 71. AstraZeneca Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. AstraZeneca Oncology Drugs Product Portfolio Table 73. AstraZeneca Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Pfizer Oncology Drugs Product Portfolio Table 78. Pfizer Recent Development Table 79. Amgen Company Information Table 80. Amgen Business Overview Table 81. Amgen Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Amgen Oncology Drugs Product Portfolio Table 83. Amgen Recent Development Table 84. Eli Lilly Company Information Table 85. Eli Lilly Business Overview Table 86. Eli Lilly Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Eli Lilly Oncology Drugs Product Portfolio Table 88. Eli Lilly Recent Development Table 89. AbbVie Company Information Table 90. AbbVie Business Overview Table 91. AbbVie Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. AbbVie Oncology Drugs Product Portfolio Table 93. AbbVie Recent Development Table 94. Takeda Company Information Table 95. Takeda Business Overview Table 96. Takeda Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Takeda Oncology Drugs Product Portfolio Table 98. Takeda Recent Development Table 99. Astellas Company Information Table 100. Astellas Business Overview Table 101. Astellas Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 102. Astellas Oncology Drugs Product Portfolio Table 103. Astellas Recent Development Table 104. Ipsen Company Information Table 105. Ipsen Business Overview Table 106. Ipsen Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 107. Ipsen Oncology Drugs Product Portfolio Table 108. Ipsen Recent Development Table 109. Sanofi Company Information Table 110. Sanofi Business Overview Table 111. Sanofi Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 112. Sanofi Oncology Drugs Product Portfolio Table 113. Sanofi Recent Development Table 114. Bayer Company Information Table 115. Bayer Business Overview Table 116. Bayer Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 117. Bayer Oncology Drugs Product Portfolio Table 118. Bayer Recent Development Table 119. Biogen Idec Company Information Table 120. Biogen Idec Business Overview Table 121. Biogen Idec Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 122. Biogen Idec Oncology Drugs Product Portfolio Table 123. Biogen Idec Recent Development Table 124. Teva Company Information Table 125. Teva Business Overview Table 126. Teva Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 127. Teva Oncology Drugs Product Portfolio Table 128. Teva Recent Development Table 129. Otsuka Company Information Table 130. Otsuka Business Overview Table 131. Otsuka Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 132. Otsuka Oncology Drugs Product Portfolio Table 133. Otsuka Recent Development Table 134. Eisai Company Information Table 135. Eisai Business Overview Table 136. Eisai Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 137. Eisai Oncology Drugs Product Portfolio Table 138. Eisai Recent Development Table 139. Merck KGaA Company Information Table 140. Merck KGaA Business Overview Table 141. Merck KGaA Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 142. Merck KGaA Oncology Drugs Product Portfolio Table 143. Merck KGaA Recent Development Table 144. Gilead Sciences Company Information Table 145. Gilead Sciences Business Overview Table 146. Gilead Sciences Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 147. Gilead Sciences Oncology Drugs Product Portfolio Table 148. Gilead Sciences Recent Development Table 149. North America Oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 150. North America Oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 151. North America Oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 152. North America Oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 153. North America Oncology Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. North America Oncology Drugs Market Size by Country (2021-2026) Table 155. North America Oncology Drugs Market Size by Country (2027-2032) Table 156. Europe Oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 157. Europe Oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 158. Europe Oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 159. Europe Oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 160. Europe Oncology Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. Europe Oncology Drugs Market Size by Country (2021-2026) Table 162. Europe Oncology Drugs Market Size by Country (2027-2032) Table 163. China Oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 164. China Oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 165. China Oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 166. China Oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 167. Asia Oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 168. Asia Oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 169. Asia Oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 170. Asia Oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 171. Asia Oncology Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 172. Asia Oncology Drugs Market Size by Country (2021-2026) Table 173. Asia Oncology Drugs Market Size by Country (2027-2032) Table 174. South America, Middle East & Africa Oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 175. South America, Middle East & Africa Oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 176. South America, Middle East & Africa Oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 177. South America, Middle East & Africa Oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 178. South America, Middle East & Africa Oncology Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 179. South America, Middle East & Africa Oncology Drugs Market Size by Country (2021-2026) Table 180. South America, Middle East & Africa Oncology Drugs Market Size by Country (2027-2032) Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Oncology Drugs Product Image Figure 2. Global Oncology Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Oncology Drugs Market Share by Type: 2025 VS 2032 Figure 4. Chemotherapy Image Figure 5. Targeted Therapy Image Figure 6. Immunotherapy (Biologic Therapy) Image Figure 7. Hormonal Therapy Image Figure 8. Others Image Figure 9. Global Oncology Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Oncology Drugs Market Share by Application: 2025 VS 2032 Figure 11. Blood Cancer Image Figure 12. Breast Cancer Image Figure 13. Gastrointestinal Cancer Image Figure 14. Prostate Cancer Image Figure 15. Respiratory or Lung Cancer Image Figure 16. Others Image Figure 17. Global Oncology Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 19. Global Oncology Drugs Market Share by Region: 2025 VS 2032 Figure 20. Years Considered Figure 21. Global Oncology Drugs Market Share by Players in 2025 Figure 22. Global Top 5 and 10 Oncology Drugs Players Market Share by Revenue in 2025 Figure 23. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. Global Oncology Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Oncology Drugs Revenue Market Share by Type (2021-2032) Figure 26. Global Oncology Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Oncology Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 29. North America Oncology Drugs Market Share by Type (2021-2032) Figure 30. North America Oncology Drugs Market Share by Application (2021-2032) Figure 31. North America Oncology Drugs Market Share by Country (2021-2032) Figure 32. United States Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 33. Canada Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 34. Mexico Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 35. Europe Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 36. Europe Oncology Drugs Market Share by Type (2021-2032) Figure 37. Europe Oncology Drugs Market Share by Application (2021-2032) Figure 38. Europe Oncology Drugs Market Share by Country (2021-2032) Figure 39. Germany Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 40. France Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 41. U.K. Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 42. Italy Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 43. Russia Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 44. Nordic Countries Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 45. China Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 46. China Oncology Drugs Market Share by Type (2021-2032) Figure 47. China Oncology Drugs Market Share by Application (2021-2032) Figure 48. Asia Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 49. Asia Oncology Drugs Market Share by Type (2021-2032) Figure 50. Asia Oncology Drugs Market Share by Application (2021-2032) Figure 51. Asia Oncology Drugs Market Share by Country (2021-2032) Figure 52. Japan Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 53. South Korea Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 54. Taiwan Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 55. Southeast Asia Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 56. India Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 57. Australia Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 58. South America, Middle East & Africa Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 59. South America, Middle East & Africa Oncology Drugs Market Share by Type (2021-2032) Figure 60. South America, Middle East & Africa Oncology Drugs Market Share by Application (2021-2032) Figure 61. South America, Middle East & Africa Oncology Drugs Market Share by Country (2021-2032) Figure 62. Brazil Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 63. South Africa Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 64. Saudi Arabia Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Turkey Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 66. Argentina Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 67. UAE Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 68. Egypt Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 69. Chile Oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others
Applications
  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Respiratory or Lung Cancer
  • Others
Companies covered
  • Roche
  • Celgene
  • Novartis
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck & Co.
  • AstraZeneca
  • Pfizer
  • Amgen
  • Eli Lilly
  • AbbVie
  • Takeda
  • Astellas
  • Ipsen
  • Sanofi
  • Bayer
  • Biogen Idec
  • Teva
  • Otsuka
  • Eisai
  • Merck KGaA
  • Gilead Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Oncology Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Chemotherapy
  5. 1.2.3 Targeted Therapy
  6. 1.2.4 Immunotherapy (Biologic Therapy)
  7. 1.2.5 Hormonal Therapy
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Oncology Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Blood Cancer
  12. 1.3.3 Breast Cancer
  13. 1.3.4 Gastrointestinal Cancer
  14. 1.3.5 Prostate Cancer
  15. 1.3.6 Respiratory or Lung Cancer
  16. 1.3.7 Others
  17. 1.4 Global Market Growth Prospects
  18. 1.5 Global Oncology Drugs Growth Trends by Region
  19. 1.5.1 Global Oncology Drugs Market Size by Region: 2021 VS 2025 VS 2032
  20. 1.5.2 Oncology Drugs Market Size by Region (2021-2026)
  21. 1.5.3 Oncology Drugs Market Size by Region (2027-2032)
  22. 1.6 Assumptions and Limitations
  23. 1.7 Study Goals and Objectives
  24. 1.8 Years Considered
2 Global Oncology Drugs Market Dynamics
  1. 2.1 Oncology Drugs Industry Trends
  2. 2.2 Oncology Drugs Industry Drivers
  3. 2.3 Oncology Drugs Industry Opportunities and Challenges
  4. 2.4 Oncology Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Oncology Drugs Revenue by Company (2021-2026)
  2. 3.2 Global Oncology Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Oncology Drugs Key Company Head office and Area Served
  4. 3.4 Global Oncology Drugs Company, Product Type & Application
  5. 3.5 Global Oncology Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Oncology Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Oncology Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Oncology Drugs Tier 1, Tier 2, and Tier 3
4 Oncology Drugs Market by Type
  1. 4.1 Global Oncology Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Oncology Drugs Market Size by Type (2021-2032)
  3. 4.3 Global Oncology Drugs Market Size Share by Type (2021-2032)
5 Oncology Drugs Market by Application
  1. 5.1 Global Oncology Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Oncology Drugs Market Size by Application (2021-2032)
  3. 5.3 Global Oncology Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Roche
  2. 6.1.1 Roche Company Information
  3. 6.1.2 Roche Business Overview
  4. 6.1.3 Roche Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Roche Oncology Drugs Product Portfolio
  6. 6.1.5 Roche Recent Developments
  7. 6.2 Celgene
  8. 6.2.1 Celgene Company Information
  9. 6.2.2 Celgene Business Overview
  10. 6.2.3 Celgene Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Celgene Oncology Drugs Product Portfolio
  12. 6.2.5 Celgene Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Novartis Oncology Drugs Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Oncology Drugs Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Johnson & Johnson
  26. 6.5.1 Johnson & Johnson Company Information
  27. 6.5.2 Johnson & Johnson Business Overview
  28. 6.5.3 Johnson & Johnson Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Johnson & Johnson Oncology Drugs Product Portfolio
  30. 6.5.5 Johnson & Johnson Recent Developments
  31. 6.6 Merck & Co.
  32. 6.6.1 Merck & Co. Company Information
  33. 6.6.2 Merck & Co. Business Overview
  34. 6.6.3 Merck & Co. Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Merck & Co. Oncology Drugs Product Portfolio
  36. 6.6.5 Merck & Co. Recent Developments
  37. 6.7 AstraZeneca
  38. 6.7.1 AstraZeneca Company Information
  39. 6.7.2 AstraZeneca Business Overview
  40. 6.7.3 AstraZeneca Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 AstraZeneca Oncology Drugs Product Portfolio
  42. 6.7.5 AstraZeneca Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Pfizer Oncology Drugs Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Amgen
  50. 6.9.1 Amgen Company Information
  51. 6.9.2 Amgen Business Overview
  52. 6.9.3 Amgen Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Amgen Oncology Drugs Product Portfolio
  54. 6.9.5 Amgen Recent Developments
  55. 6.10 Eli Lilly
  56. 6.10.1 Eli Lilly Company Information
  57. 6.10.2 Eli Lilly Business Overview
  58. 6.10.3 Eli Lilly Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Eli Lilly Oncology Drugs Product Portfolio
  60. 6.10.5 Eli Lilly Recent Developments
  61. 6.11 AbbVie
  62. 6.11.1 AbbVie Company Information
  63. 6.11.2 AbbVie Business Overview
  64. 6.11.3 AbbVie Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 AbbVie Oncology Drugs Product Portfolio
  66. 6.11.5 AbbVie Recent Developments
  67. 6.12 Takeda
  68. 6.12.1 Takeda Company Information
  69. 6.12.2 Takeda Business Overview
  70. 6.12.3 Takeda Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Takeda Oncology Drugs Product Portfolio
  72. 6.12.5 Takeda Recent Developments
  73. 6.13 Astellas
  74. 6.13.1 Astellas Company Information
  75. 6.13.2 Astellas Business Overview
  76. 6.13.3 Astellas Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Astellas Oncology Drugs Product Portfolio
  78. 6.13.5 Astellas Recent Developments
  79. 6.14 Ipsen
  80. 6.14.1 Ipsen Company Information
  81. 6.14.2 Ipsen Business Overview
  82. 6.14.3 Ipsen Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Ipsen Oncology Drugs Product Portfolio
  84. 6.14.5 Ipsen Recent Developments
  85. 6.15 Sanofi
  86. 6.15.1 Sanofi Company Information
  87. 6.15.2 Sanofi Business Overview
  88. 6.15.3 Sanofi Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Sanofi Oncology Drugs Product Portfolio
  90. 6.15.5 Sanofi Recent Developments
  91. 6.16 Bayer
  92. 6.16.1 Bayer Company Information
  93. 6.16.2 Bayer Business Overview
  94. 6.16.3 Bayer Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Bayer Oncology Drugs Product Portfolio
  96. 6.16.5 Bayer Recent Developments
  97. 6.17 Biogen Idec
  98. 6.17.1 Biogen Idec Company Information
  99. 6.17.2 Biogen Idec Business Overview
  100. 6.17.3 Biogen Idec Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Biogen Idec Oncology Drugs Product Portfolio
  102. 6.17.5 Biogen Idec Recent Developments
  103. 6.18 Teva
  104. 6.18.1 Teva Company Information
  105. 6.18.2 Teva Business Overview
  106. 6.18.3 Teva Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Teva Oncology Drugs Product Portfolio
  108. 6.18.5 Teva Recent Developments
  109. 6.19 Otsuka
  110. 6.19.1 Otsuka Company Information
  111. 6.19.2 Otsuka Business Overview
  112. 6.19.3 Otsuka Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Otsuka Oncology Drugs Product Portfolio
  114. 6.19.5 Otsuka Recent Developments
  115. 6.20 Eisai
  116. 6.20.1 Eisai Company Information
  117. 6.20.2 Eisai Business Overview
  118. 6.20.3 Eisai Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Eisai Oncology Drugs Product Portfolio
  120. 6.20.5 Eisai Recent Developments
  121. 6.21 Merck KGaA
  122. 6.21.1 Merck KGaA Company Information
  123. 6.21.2 Merck KGaA Business Overview
  124. 6.21.3 Merck KGaA Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 Merck KGaA Oncology Drugs Product Portfolio
  126. 6.21.5 Merck KGaA Recent Developments
  127. 6.22 Gilead Sciences
  128. 6.22.1 Gilead Sciences Company Information
  129. 6.22.2 Gilead Sciences Business Overview
  130. 6.22.3 Gilead Sciences Oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  131. 6.22.4 Gilead Sciences Oncology Drugs Product Portfolio
  132. 6.22.5 Gilead Sciences Recent Developments
7 North America
  1. 7.1 North America Oncology Drugs Market Size (2021-2032)
  2. 7.2 North America Oncology Drugs Market Size by Type
  3. 7.2.1 North America Oncology Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America Oncology Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America Oncology Drugs Market Share by Type (2021-2032)
  6. 7.3 North America Oncology Drugs Market Size by Application
  7. 7.3.1 North America Oncology Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America Oncology Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America Oncology Drugs Market Share by Application (2021-2032)
  10. 7.4 North America Oncology Drugs Market Size by Country
  11. 7.4.1 North America Oncology Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Oncology Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America Oncology Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America Oncology Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Oncology Drugs Market Size (2021-2032)
  2. 8.2 Europe Oncology Drugs Market Size by Type
  3. 8.2.1 Europe Oncology Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe Oncology Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe Oncology Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe Oncology Drugs Market Size by Application
  7. 8.3.1 Europe Oncology Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe Oncology Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe Oncology Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe Oncology Drugs Market Size by Country
  11. 8.4.1 Europe Oncology Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Oncology Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe Oncology Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe Oncology Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Oncology Drugs Market Size (2021-2032)
  2. 9.2 China Oncology Drugs Market Size by Type
  3. 9.2.1 China Oncology Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China Oncology Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China Oncology Drugs Market Share by Type (2021-2032)
  6. 9.3 China Oncology Drugs Market Size by Application
  7. 9.3.1 China Oncology Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China Oncology Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China Oncology Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Oncology Drugs Market Size (2021-2032)
  2. 10.2 Asia Oncology Drugs Market Size by Type
  3. 10.2.1 Asia Oncology Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia Oncology Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia Oncology Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia Oncology Drugs Market Size by Application
  7. 10.3.1 Asia Oncology Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia Oncology Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia Oncology Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia Oncology Drugs Market Size by Country
  11. 10.4.1 Asia Oncology Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Oncology Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia Oncology Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia Oncology Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Oncology Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Oncology Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Oncology Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Oncology Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Oncology Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Oncology Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Oncology Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Oncology Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Oncology Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Oncology Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Oncology Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Oncology Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Oncology Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Oncology Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst